Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nasus PharmaNSRX 14 3-1 Month Momentum % is -5.31% as of Aug. 31, 2026. GuruFocus rates NSRX with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 1,022 Drug Manufacturers companies, Nasus Pharma ranks worse than 54.4% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-31), Nasus Pharma's 3-1 Month Momentum % is -5.31%.
The industry rank for Nasus Pharma's 3-1 Month Momentum % or its related term are showing as below:
NSRX's 3-1 Month Momentum % is ranked worse than 54.4% of 1022
companies
in the Drug Manufacturers industry
Industry Median: -3.54
vs NSRX: -5.31
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Nasus Pharma 3-1 Month Momentum % Related Terms
NSRX vs SCLX, MIRA, MDCX: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - General subindustry, Nasus Pharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nasus Pharma 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nasus Pharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Nasus Pharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nasus Pharma (NSRX) has a 3-1 Month Momentum % of -5.31% as of Aug. 31, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Nasus Pharma and its competitors. According to the industry distribution chart, Nasus Pharma ranks #556 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 54.4%.
Is Nasus Pharma's 3-1 Month Momentum % too high?
Nasus Pharma's current 3-1 Month Momentum % is -5.31%. Based on the distribution chart, Nasus Pharma ranks #556 out of 1022 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Nasus Pharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Nasus Pharma's 3-1 Month Momentum % compare to SCLX and MIRA?
According to the Drug Manufacturers industry distribution chart, Nasus Pharma ranks #556 out of 1022 companies for 3-1 Month Momentum %. This places Nasus Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Nasus Pharma and its competitors. Nasus Pharma's current 3-1 Month Momentum % is -5.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasus Pharma stock overvalued right now?
Nasus Pharma (NSRX) has a current 3-1 Month Momentum % of -5.31%. The current 3-1 Month Momentum % is -5.31%. Nasus Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Nasus Pharma (NSRX), the current 3-1 Month Momentum % is -5.31% as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
14GF Score
Get the complete analysis for NSRX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSRX has been successfully added to your 
